Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

HMS Immunology and Microbiology > Cancer Immunology > Flashcards

Cancer Immunology Flashcards

You may prefer our related Brainscape-certified flashcards:
Biology 101 flashcards
1
Q

Penetrance of tumors by T cells. . .

A

. . . improves prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Adoptive transfer of T cells in mouse tumor models

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

neoantigens

A

The result of self proteins that are mutated as either a driver or passenger mutation in cancer. These are a potential source of foreigness signal in tumors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Malignant tumors often _____ express _____ antigens.

A

Malignant tumors often abnormally express normal antigens.

This may lead to failure of tolerance against these antigens, provoking an immune response against the tumor, but also presenting the possibility of autoimmunity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Oncogenic viral antigens

A

Some cancers are the result of viral activity, and so targeting immunity against the virus is synonymous with targeting immunity against the cancer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Cancer-germline/cancer testis antigens

A
  1. Normally expressed only in testis, fetal ovaries, and trophoblasts
  2. Frequently expressed in cancer cells
  3. Not responsible for malignant phenotype
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

HER2/neu

A
  1. An epidermal growth factor receptor (EGFR) family receptor
  2. Overexpressed due to gene amplification in some breast cancers
  3. Contributes to malignant phenotype
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

prostate specific antigen

A

or PSA

expressed by normal and malignant prostate epithelial cells

Tissue differentiation antigen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

tyrosinase

A

expressed by normal and malignant melanocytes

Tissue differentiation antigen​

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

CD19

A

expressed by normal and malignant B lymphocytes

Tissue differentiation antigen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Derepression expression antigens

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

____ may overcome self tolerance, leading to killing of tumor cells.

A

Aberrant, uncontrolled overexpression may overcome self tolerance, leading to killing of tumor cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Mechanisms of tumor immunity

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which Immune Mechanisms are used to reject tumors?

A
  • CD8+ CTL mediated killing-antigen specific (most and best evidence)
  • CD4+ Th mediated help for CD8 T cells, classical macrophage activation.
  • Th1 cells appear to be bad for the tumor; (Th2 responses are bad for the patient)
  • Classical activation/M1 phenotype bad for tumor (alternative activation/M2 phenotype bad for patient)
  • NK cell mediated killing
  • Antibody mediated killing (opsonization and complement, ADCC)
  • Not much evidence that endogenous antibody responses are effective
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Tumor evasion of CTL immunity

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Immunity induction checkpoint

A
17
Q

Cytotoxicity checkpoint

A
18
Q

Myeloid-derived suppressor cells

A
  • Potent immunosuppressive activity
  • formed in the bone marrow and, migrate to secondary lymphoid organs and the tumor
  • Immunosuppressive expression of arginase, iNOS , TGF-β, IL-10 , and COX2
  • Sequestration of cysteine
  • Induction of Tregs
19
Q

Differentiation of MDSCs

A
20
Q

Immunosuppressive tumor microenvironment

A
21
Q

Immune editing

A

The result of natural selection within the tumor microenvironment in response to the selective pressure of the adaptive immune system

22
Q

CAR T cell therapy is currently used primarily for. . .

A

. . . B cell lymphoma, specifically against CD19.

23
Q

Types of mAbs used in cancer therapy

A
  • Some bind antigens on cancer cells targeting them for destruction by phagocytes, NK cells or complement
  • Some bind soluble growth factors for tumors
  • Some block activing receptors/growth factor receptors on cancer cells
  • Some block checkpoints to enhance T cell responses
24
Q

Conjugated monoclonal antibody cancer therapies

A
  • mAbs joined to a chemotherapy drug or to a radioactive particle
  • The mAb brings drugs or radioisotope directly to the cancer cells.
25
Q

Bispecific monoclonal antibodies

A
  • These drugs are made up 2 different mAb binding sites
  • They bind 2 different proteins at the same time
  • One part binds tumor, the other part binds to a T cell
  • Brings the cancer cells and immune cells together
26
Q

Clinical outcomes for checkpoint blockade therapy

A

~30-60 % objective response rates, with many long term survivors with no disease progression

27
Q

The genomes of cancers deficient in ____ contain exceptionally high numbers of somatic mutations.

A

The genomes of cancers deficient in mismatch repair contain exceptionally high numbers of somatic mutations.

As a result, PD1-blockade is substantially more effective against these tumors.

28
Q

Side effects of checkpoint blockade

A

Overall about 50-60 % of patients have immune complications

29
Q

TSA vaccines

A
30
Q

CAR T cells utilize a recombinant. . .

A

. . . BCR

NOT a TCR. Think about it, they recognize a whole protein, it cannot be a TCR otherwise it would need to recognize a peptide.

31
Q

The main evasion strategy of Hodgkin lymphoma is ____.

A

The main evasion strategy of Hodgkin lymphoma is PD-L1 expression.

Presumably because there is already some at baseline and less of a barrier to upregulate it.

32
Q

The monospot test is a test for. . .

A

. . . naive B cells that have been aberrantly activated, bypassing conventional activation pathways.

33
Q

Oligoclonality

A

If you stain for a particular TCR chain, and if most of the cells in the tumor have the same chain, you may presume that they are likely clonal.

HMS Immunology and Microbiology (27 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions